BIOMAT Database Logo BIOMAT Database Logo

Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide. 1993

J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
Leukemia/Bone Marrow Transplantation Program of British Columbia, Vancouver General Hospital, Canada.

Twenty-three patients greater than age 60 years with acute myelogenous leukemia (AML) received induction therapy with continuous infusion cytosine arabinoside (1.5 g/m2/day, day 1-3), mitoxantrone (10 mg/m2/day, day 1-3) and etoposide (800 mg/m2, day 4). Patients entering complete remission (CR) were eligible to receive an identical consolidation cycle. Eighteen of the 23 patients (78%; 95% confidence interval 56% to 93%) entered CR. Twelve of these received consolidation therapy and 4 of these remain in remission at 3 to 20 months. Hematologic toxicity of the regimen was acceptable; only 1 patient died following therapy (having attained a CR). Non-hematologic toxicity was mostly mild (grade 2 or less) with one episode of grade 3 cerebellar toxicity. While this regimen induces a high CR rate in patients > age 60 years, relapses remain common and overall survival is too early to assess.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.
August 1988, Cancer,
J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia.
January 1990, Haematology and blood transfusion,
J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone.
June 1987, Seminars in oncology,
J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
December 1993, Seminars in oncology,
J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
September 1990, American journal of hematology,
J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
Intensive induction therapy with behenoyl, cytosine arabinoside, daunorubicin, and 6-mercaptopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine, and intermediate-dose continuous cytarabine (M-85 protocol) for adult acute myelogenous leukemia.
January 1990, Haematology and blood transfusion,
J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
[Intermediate-dose cytosine arabinoside therapy in refractory acute leukemia].
January 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
Successful re-induction therapy for acute myelogenous leukemia with cytosine arabinoside and daunorubicin.
January 1979, Cancer treatment reports,
J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
[Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy].
July 1995, [Rinsho ketsueki] The Japanese journal of clinical hematology,
J D Shepherd, and D E Reece, and M J Barnett, and H G Klingemann, and S H Nantel, and H J Sutherland, and G L Phillips
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
June 1996, Leukemia & lymphoma,
Copied contents to your clipboard!